LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy

Atherosclerosis

Volumn 151, Issue 2, 2000, Pages 551-557

  Arosio, M ^a   Sartore, G ^b   Rossi, C M ^c   Casati, G ^a   Faglia, G ^a   Manzato, E ^b   Barbarino, A ^d   Cannavo, S ^e   Ciccarelli, E ^f   Giusti, M ^g   Squatrito, S ^h   Tamburrano, G ⁱ  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Italfarmaco SpA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acromegaly; Apo(a)isoform; Lipoprotein(a); Lipoproteins; Octreotide; Small dense low density lipoprotein; Somatostatin analogs

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCAGON; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADRENAL FUNCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DIABETES MELLITUS; FEMALE; HORMONE RESPONSE; HUMAN; LIPID BLOOD LEVEL; MALE; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 0033867735     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00426-8     Document Type: Article

References (34)

1. Bates A.S., Van't Hoff W., Jones J.M., Clayton R.N. An audit of outcome of treatment in acromegaly. Qrt. J. Med. 86:1993;293-299.
2. Rajasoorya C., Holdaway I.M., Wrightson P., Scott D.J., Ibbertson H.K. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. 41:1994;95-102.
3. Arosio M., Macchelli S., Rossi C.M. et al. Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study. Eur. J. Endocrinol. 133:1995;430-439.
4. Lamarche B., Tchernof A., Moorjani S. et al. Small, dense low-density lipoprotein particles as predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 95:1997;69-75.
5. Nosadini R., Manzato E., Solini A. et al. Peripheral, rather than hepatic, insulin resistance and atherogenic lipoprotein phenotype predict cardiovascular complications in NIDDM. Eur. J. Clin. Invest. 24:1994;258-266.
6. Tan K.C.B., Shiu S.W.M., Janus E.D., Lam K.S.L. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis. 129:1997;59-65.
7. Kostner G.M., Avogaro P., Cazzolato G., Marth E., Bittolo-Bon G., Quinci G.B. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 38:1981;51-61.
8. Rosengren A., Wilhelmsen L., Eriksson E., Risberg B., Wedel H. Lipoprotein (a) and coronary heart disease in a general population sample of middle-aged men. Brit. Med. J. 301:1990;1248-1250.
9. Bostom A.G., Cupples L.A., Jenner J.L. et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. 276:1996;544-548.
10. Lam K.S.L., Pang R.W.C., Janus E.D., Kung A.W.C., Wang C.C.L. Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly. Atherosclerosis. 104:1993;183-188.
11. Mooser V., Hobbs H.H. Lipoprotein(a) and growth hormone: is the puzzle solved? Eur. J. Endocrinol. 137:1997;450-452.
12. The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197.
13. Roschlau V.P., Bernt E., Gruber W. Enzymatische Bestimmung des Gesamt Cholesterins in Serum. Klin. Chem. Klin. Biochem. 12:1974;403-407.
14. Lipid Research Clinics Program. Lipid and lipoprotein analysis. In: US Department of Health and Human Service, editor. Manual of Laboratory Operations, 2nd edition, Washington DC, 1982: 63-77.
15. Wahlefeld A.W. Triglycerides determination after enzymatic hydrolysis. Bergmeyer H.U. Methods of Enzymatic Analysis. 1976;1831-1835 Academic Press, 1976, New York.
16. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
17. Chung B.H., Wilkinson T., Geer J.C., Segrest J.P. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J. Lipid. Res. 21:1980;284-291.
18. Chung B.H., Segrest J.P., Ray M.J. et al. Single vertical spin density gradient ultracentrifugation. Segrest J.P., Albers J.J. Methods in Enzymology, vol 128. Plasma Lipoproteins: Preparation, Structure and Molecular Biology. 1986;181-209 Academic Press, Orlando, FL.
19. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmier H.G., Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. Invest. 80:1987;458-465.
20. Barreca A., Ciccarelli E., Minuto F., Bruzzi P., Giordano G., Camanni F. Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly. Acta. Endocrinol. 120:1989;635-639.
21. James R.A., Møller N., Chatterjee S., White M., Kendall-Taylor P. Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide. Diabetic Med. 8:1991;517-523.
22. Sassolas G., Harris A.G., James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J. Clin. Endocrinol. Metab. 71:1990;391-397.
23. Cohen R., Chanson P., Bruckert E. et al. Effects of octreotide on lipid metabolism in acromegaly. Horm. Metab. Res. 24:1992;397-400.
24. Simsolo R.B., Ezzat S., Ong J.M., Saghizadeh M., Kern P.A. Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase. J. Clin. Endocrinol. Metab. 80:1995;3233-3238.
25. Wildbrett J., Hanefeld M., Fucker K. et al. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp. Clin. Endocrinol. Diabetes. 105:1997;331-335.
26. Rudling M., Norstedt G., Olivecrona H., Reihnér E., Gustafsson J.-Å., Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc. Natl. Acad. Sci. USA. 89:1992;6983-6987.
27. Murase T., Yamada N., Ohsawa N., Kosaka K., Morita S., Yoshida S. Decline of postheparin plasma lipoprotein lipase in acromegalic patients. Metabolism. 29:1980;666-672.
28. Fineberg S.E., Merimee T.J., Rabinowitz D., Edgar P.J. Insulin secretion in acromegaly. J. Clin. Endocrinol. Metab. 30:1970;288-292.
29. Hansen I., Tsalikian E., Beaufrere B., Gerich J., Haymond M., Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extra-hepatic insulin action. Am. J. Physiol. 250:1986;269-273.
30. Zambon S., Manzato E., Solini A. et al. Lipoprotein abnormalities in non-insulin-dependent diabetic patients with impaired extrahepatic insulin sensitivity, hypertension, and microalbuminuria. Arterioscler. Thromb. 14:1994;911-917.
31. Zambon A., Austin M.A., Brown B.G., Hokanson J.E., Brunzell J.D. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler. Thromb. 13:1993;147-152.
32. Ho K.K., Jenkins A.B., Furler S.M., Borkman M., Chisholm D.J. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin. Endocrinol. 36:1992;271-279.
33. Sato K., Takamatsu K., Hashimoto K. Short-term effects of octreotide on glucose tolerance in patients with acromegaly. Endocrinol. J. 42:1995;739-745.
34. Laron Z., Wang X.L., Klinger B., Silbergeld A., Wilcken D.E.L. Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome. Metabolism. 45:1996;1263-1266.